BioSpace News Archive

Sanara MedTech Inc. announced the first sale of ALLOCYTE® Plus Advanced Viable Bone Matrix.

Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced that it has fully enrolled patients in Cohort 1 of its Phase 1 clinical study to evaluate TGN-S11, its first drug candidate, in patients with HPV-associated cancers.

Xēnix Medical, a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nanotechnology designation of its neoWave™ line of interbody fusion implants featuring proprietary NANOACTIV™ surface technology.

Rancho BioSciences, the leading Data Science Services company based in San Diego, CA, is pleased to announce its participation in the upcoming 2023 CDISC US Interchange.

IRLAB Therapeutics IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has secured top expertise in supporting the preparations for Phase III with mesdopetam.

Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies, is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.

Royal Philips, a global leader in health technology, has announced the interoperability of Philips Capsule Medical Device Information Platform with Philips Patient Information Center iX, providing hospitals with a first-of-its-kind, comprehensive patient overview.

Couragene, a genetic medicines company using novel delivery platforms, announces that its co-founders Yong-Hui Jiang and Jiangbing Zhou of Yale University, together with Elizabeth Berry-Kravis of RUSH University have been awarded a competitive UG3/UH3 grant from the NIH’s Somatic Cell Genome Editing program.

Sibylla Biotech announces the appointment of Sonia Poli, Ph.D., as Chief Scientific Officer.

NanOlogy LLC announced that initial safety and clinical outcomes from a Phase 2 clinical trial of intratumoral large surface area microparticle paclitaxel in locally advanced pancreatic cancer were published online ahead of print in Pancreas and two posters were presented at the ninth AACR Special Conference on Pancreatic Cancer in Boston reporting downstaging and immune data from the trial.